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Literature and experimental data relevant to the decision to
allow a waiver of in vivo bioequivalence (BE) testing for ap-
proval of immediate release (IR) solid dosage forms containing
moxifloxacin hydrochloride as the API manufactured by the
Government Pharmaceutical Organization (GPO) are evalu-
ated.The solubility of moxifloxacin hydrochloride determined
by the shake flask method in six different pH mediums (1.2,
4.5, 5.4, 6.4, 6.8 and 7.5) was 4.988 ± 0.1962, 27.012 ± 0.4138,
21.668 ± 0.5165, 47.200 ± 0.8095, 73.438 ± 1.7310 and
196.475 ± 4.4624 mg/mL, respectively. The Dose/Solubility (D/
S) Ratio of the highest strength (400 mg) available in the market
of moxifloxacin tablets was 80.192, 14.808, 18.460, 8.475, 5.447
and 2.036 mL, respectively.Therefore, the moxifloxacin hydro-
chloride can be classified as highly soluble drug since highest
dose strength of drug can solute in 250 mL or less of aqueous
medium over the pH range of 1–7.5 [1]. Likewise, the absolute
bioavailability of moxifloxacin is approximately 90% [2]. Hence,
moxifloxacin hydrochloride can be assigned to BCS Class I as
high solubility and high permeability. Furthermore,moxifloxacin
is not narrow therapeutic index drug according to the defini-
tion of narrow therapeutic drugs by United States Code of
Federal Regulations [3]. Additionally, the excipients used are
widely used in conventional formulation, have no unex-
pected influence on the bioavailability of the product and the
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quantity of each excipient is within a maximum potency as
per U.S. FDA inactive ingredient search for approved drug
products. Moreover, dissolution profiles of both the Moxiflox
GPO 400 mg tablets and the reference product (Avelox® 400 mg
tablets manufactured by Bayer PharmaAG) are similar as shown
in Fig. 1. Additionally, both products are considered as very
rapidly dissolving since they release at least 85% of content
in 15 minutes in three different buffers (pH 1.2, 4.5 and 6.8)
[1]. Moreover, the Moxiflox GPO is not designed for absorp-
tion in the oral cavity. Finally, risk assessment on biowaiver-
based equivalence decision in terms of public health and
individual patient risks was outweighed by the potential ben-
efits of the biowaiver approach. Based on this evidence, the IR
solid dosage forms containing moxifloxacin hydrochloride
manufactured by GPO are eligible for biowaiver of in vivo
bioequivalence (BE) testing.
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Fig. 1 – Dissolution profiles of the Moxiflox GPO 400 mg tablets and the reference product in (A) 0.1 N HCl pH 1.2, (B) buffer
pH 4.5 and (C) buffer pH 6.8.
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